In the first report of the Aldose Reductase Inhibitor–Diabetes Complications Trial the epalrestat and control groups had 289 and 305 subjects, respectively [6], but in this study these numbers were 52 and 57, respectively. This evidence concerns the gene AKR1B1 and diabetes mellitus.